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Abstract 
Recently, human leukocyte lastase has been detected in human eosinophils. Reinvestigating these findings, 2.5 pg active human 
leukocyte lastase (E.C. 3.4.21.37) were found per neutrophil isolated from peripheral blood, whereas the elastase activity of eosinophil 
preparations was linearly correlated with the content of contaminating eutrophils. Also spontaneous or stimulated release of active 
elastase was absent in eosinophils. By immunohistochemistry no elastase immunoreactivity could be demonstrated in human eosinophils. 
Therefore, we conclude that human eosinophils do not contain considerable amounts of human leukocyte lastase. 
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1. Introduction 
Human leukocyte elastase (HLE), a serine protease 
present in the azurophilic granules of neutrophils [1], is 
known to be involved in the tissue destruction of a broad 
variety of inflammatory diseases, e.g., lung emphysema 
[2]. It has been reported that human eosinophils contain 
HLE activity in concentrations accounting for approx. 
22.5% of the HLE activity present in human neutrophils 
[3]. To reinvestigate these findings we isolated human 
eosinophils and neutrophils, carefully checking for purity 
and contaminating leukocytes and determined the HLE 
activity in lysates and supernatants after stimulation. In 
addition, cell smears and histological sections were stained 
for HLE immunoreactivity. 
2. Materials and methods 
2.1. Preparation of neutrophils and eosinophils 
Leukocytes were prepared by citrate dextrane sedimen- 
tation and a discontinuous percoll gradient according to 
Ref. [4]. Resulting eosinophil preparations were carefully 
checked for contaminating eutrophils in cytospin samples. 
Leukocytes were identified by May Griinwald and Giemsa 
staining according to Pappenheim (differential count of 
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500 cells). The eosinophil preparations howed 87.2- 
100.0% purity (n = 43), as contaminating cells only poly- 
morphonuclear cells were observed. The resulting neu- 
trophil preparations showed 90.0-100.0% purity. On aver- 
age the neutrophil preparations contained 95.0% neu- 
trophils, 2.3% eosinophils, 1.4% lymphocytes, 1.0% 
monocytes and 0.3% basophils as contaminants. 
2.2. Elastase and cathepsin G activities 
Cells were lysed with 0.1% Triton X-100. HLE and 
cathepsin G activities were determined using methoxysuc- 
cinyl-alanyl-alanyl-prolyl-valine-p-nitroanilide (Meosuc- 
Ala-Ala-Pro-Val-NA, Sigma) and succinyl-alanyl-alanyl- 
prolyl-phenylalanine-p-nitroanilide (Suc-Ala-Ala-Pro-Phe- 
NA, Sigma) as specific substrates according to Ref. [5]. 
Substrate solutions in 0.1 M HEPES, 0.5 M NaC1, 10% 
Me2SO (pH 7.4), were prepared from stock solutions of 
the substrates (0.1 M in M%SO). Released p-nitroaniline 
was spectrophotometrically quantitated at 405 nm after 
incubation of the samples for 1-69 h at 25°C. The reaction 
was proven to be linear up to 72 h (for both enzymes as 
well as cell lysates). Activities were corrected for the low 
but detectable rate of spontaneous hydrolysis of both sub- 
strates under the conditions employed. One unit HLE was 
defined as the release of 1 nmol p-nitroaniline per min. 
Activities were compared with the activities of human 
sputum elastase (identical to HLE) and human sputum 
cathepsin G (Elastin Products Co, MO, USA). Active sites 
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were titrated with recombinant elafin or eglin C respec- 
tively. 
2.3. Stimulated elastase and cathepsin G release 
Neutrophils or eosinophils were suspended in phos- 
phate-buffered saline (PBS; 10 6 cells/ml). Cells were 
preincubated for 5 min at 37°C with cytochalasin B (5 
/zg/ml). 150 /zl cell suspension were stimulated with 150 
/~1 recombinant complement split product C5a (Sigma; 100 
/zg/ml), recombinant interleukin 8 (Pepro Tech Inc., 
Rocky Hill, USA; 100 /zg/ml), or N-formyl-methionyl- 
leucyl-phenylalanine (Sigma; 10 -6 M) for 30 min at 37°C 
in comparison with buffer and 0.1% Triton X-100 controls. 
Cells were separated by centrifugation with 500 × g and 
elastase release was measured in 50 ~1 supernatant by the 
addition of 100 /zl of 2 mM Meosuc-Ala-Ala-Pro-Val-NA 
in 0.1 M HEPES, 0.5 M NaC1, 10% MezSO (pH 7.5). All 
experiments were performed in duplicate. 
3. Results 
Lysed neutrophils contained 2.5 pg HLE per neutrophil, 
whereas the HLE activity of eosinophil preparations was 
linearly correlated with the their content of contaminating 
neutrophils (Fig. 1). Furthermore the presence of HLE in 
eosinophil preparations was always accompanied by the 
presence of cathepsin G in a fixed ratio (data not shown). 
This provides further evidence that the HLE in eosinophil 
preparations i  derived from contaminating neutrophils, in 
which HLE and cathepsin G are stored within the same 
granules. 
mU elaetaee 
60 y = -2,83 + 3,41 x 
r = 0970 
50 n = 43 " 
, o  
30 • 
20 f ~  
10 
i ~ , i i i i i J 
0 2 4 6 8 10 12 14 16 
% neutrophil$ in eosinophil preparation 
Fig. 1. Elastase activity (Meosuc-Ala-Ala-Pro-Val-NA hydrolysis) of 
eosinophil preparations in relation to contaminating eutrophils. 1.5 × 104 
cells derived from 43 different individuals were lysed in 75 pA phosphate 
buffered saline+0.1% Triton X-100 and added to 1.425 ml substrate (2 
mM). HLE activity was followed spectrophotometrically at 405 nm 
(shown: mean of duplicates, linear regression and 95%-confidence inter- 
vail). Cytospins of the cell preparations were stained for a differential 
count of eosinophils and neutrophils. 
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Fig. 2. Elastase release of stimulated neutrophils. 1.5 × 105 neutrophils 
98.0-100.0 pure (A) and 1.5 x 105 eosinophils containing 10% contami- 
nating neutrophils (B) in 150 /zl phosphate-buffered saline were stimu- 
lated in the presence of cytochalasin B (5 ~g/ml )  with 150 /~1 comple- 
ment C5a (100 /zg/ml), interleukin 8 (100 /~g/ml), and N-formyl- 
methionyl-leucyl-phenylalanine (10 -6 M). Elastase release was deter- 
mined by measuring the Meosuc-Ala-Ala-Pro-Val-NA hydrolysis of cell 
free supernatants (mean of six duplicates). 
To exclude the presence of cytosolic inhibitors of HLE 
in eosinophils, which might inhibit the HLE activity during 
lysis of eosinophils, the stimulated HLE release was deter- 
mined. After stimulation with FMLP, complement split 
product C5a and interleukin 8 (in the presence of cyto- 
chalasin B) HLE was released from neutrophils (Fig. 2A) 
by the same stimuli and to the same relative xtent as from 
eosinophil preparations containing 10% contaminating 
neutrophils (Fig. 2B). The stimulated HLE release from 
eosinophil preparations was again correlated with the con- 
tent of contaminating neutrophils (Fig. 3). The HLE re- 
lease was quantitatively consistent with the expected re- 
lease from contaminating neutrophils. Similar results have 
been obtained with cathepsin G release (data not shown). 
Staining of cell smears or cytospins with anti-HLE 
antibodies (monoclonal, DAKO and polyclonal sheep anti- 
serum, SEROTEC) resulted in strong staining of neu- 
trophils and light but clear unspecific membrane staining 
of all other leukocytes and erythrocytes. No specific 
eosinophil staining was observed. In addition, we have not 
seen any HLE-immunoreactivity in eosinophils in histo- 
logic sections of dermatitis herpetiformis using a poly- 
clonal sheep antiserum and a monoclonal mouse antibody. 
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Fig. 3. Elastase release of stimulated eosinophil preparations in relation to 
contaminating neutrophils. 1.5 × 105 cells in 150 kL1 PBS were stimulated 
in the presence of cytochalasin B (5 /xg/ml) with 150 /~1 complement 
C5a (100 /xg/ml), interleukin 8 (100 k~g/ml), and N-formyl-methionyl- 
leucyl-phenylalanine (10 -6 M). Elastase release from eosinophils derived 
from 15 different patients was determined by measuring the Meosuc-Ala- 
AIa-Pro-VaI-NA hydrolysis of cell free supernatants (duplicates). Cy- 
tospins of the eosinophil preparations were stained for a differential count 
of eosinophils and neutrophils. 
Therefore, we conclude from our experiments that 
eosinophils do not contain detectable amounts of HLE. 
trophils in these preparations. By linear extrapolation of 
the eosinophil preparations to 0% neutrophil contamina- 
tion, we could not detect any HLE activity in eosinophils. 
Human neutrophils are known to contain a cytosolic 
inhibitor of HLE in a concentration of 1 attomol/cell [7]. 
To exclude the possibility that eosinophils contain major 
amounts of a cytosolic inhibitor, which would inactivate 
HLE during lysis of eosinophils, we investigated the stimu- 
lated enzyme release of eosinophils. There was no evi- 
dence that eosinophils release significant amounts of enzy- 
matically active HLE. 
The absence of HLE in eosinophils is further substanti- 
ated by the observation that eosinophil precursors in the 
bone marrow did not express mRNA for HLE in contrast 
to precursor cells of the neutrophil lineage [8]. The finding 
that we could not detect HLE-immunoreactivity n tissue 
sections is in good agreement with the finding of Fujisawa 
et al. [9] who demonstrated HLE in neutrophils but not in 
eosinophils in immunohistochemistry. 
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4. Discussion 
HLE is generally accepted to be a major matrix degrad- 
ing protease in neutrophils able to induce tissue damage in 
neutrophil-rich inflammatory diseases. The current con- 
cepts about the development of lung emphysema include 
the involvement of HLE being one of the major tissue 
destroying agents [6]. This concept is mainly based on the 
observation that HLE instilled into the airways of animals 
produces emphysema-like lung destruction and that the 
genetic deficiency of active Cel-proteinase inhibitor, the 
major elastase inhibitor of human serum, is accompanied 
by the occurrence of lung emphysema in early childhood 
(review in Ref. [2]). 
Recent findings by Lungarella nd co-workers [3] sug- 
gest that human eosinophils should contain HLE. This 
finding would appear of great relevance for allergic dis- 
eases, such as allergic asthma bronchiale and atopic der- 
matitis. In our investigations we did not find any signifi- 
cant HLE activity in eosinophil lysates. The HLE activity 
was always related to the number of contaminating neu- 
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